After winning a surprise approval for its hereditary angioedema drug Ekterly, KalVista is confident the oral offering will ...
Riverwater Partners, an investment management company, released its “Sustainable Value Strategy” Q4 2025 investor letter. A copy of the letter can be downloaded here. The Strategy underperformed the ...
The European Commission has approved Otsuka's Dawnzera for the prevention of recurrent attacks in rare disease hereditary angioedema (HAE), a drug that can be self-administered by patients with weeks ...
With the approval of the FDA, garadacimab can help patients with hereditary angioedema (HAE) prevent attacks by shutting down the contact pathway. Today, the FDA approved CSL’s garadacimab-gxii ...
Despite the availability of long-term prophylaxis (LTP), a substantial proportion of patients with hereditary angioedema (HAE) in Sweden continue to require repeated on-demand or short-term treatments ...
SAN ANTONIO -- Among patients with hereditary angioedema (HAE), monthly injections of the investigational biologic garadacimab reduced the mean attack rate substantially in the phase III VANGUARD ...
Initial findings from a Phase 3 efficacy trial suggest Ionis Pharmaceuticals’ RNA-targeted treatment, given monthly or bimonthly, cut angioedema attacks more than placebo, the firm said Monday. The ...
Legendary investor Warren Buffett advises to be fearful when others are greedy, and be greedy when others are fearful. One way we can try to measure the level of fear in a given stock is through a ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results